ADVAIR 100 DISKUS 50 MCG
SALMETEROL (SALMETEROL XINAFOATE) : 50 MCG FLUTICASONE PROPIONATE : 100 MCG · DIN 02240835 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is ADVAIR 100 DISKUS?
ADVAIR 100 DISKUS 50 MCG contains SALMETEROL (SALMETEROL XINAFOATE) : 50 MCG FLUTICASONE PROPIONATE : 100 MCG. It is listed in the Health Canada Drug Product Database under DIN 02240835, held by GLAXOSMITHKLINE INC, supplied as POWDER for INHALATION administration. Health Canada currently lists it as marketed, status dated 12-Mar-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ADVAIR 100 DISKUS used for?
Maintenance treatment of asthma in patients ≥4 years (Diskus) or ≥12 years (MDI). Maintenance treatment of COPD (including emphysema and chronic bronchitis) for ADVAIR DISKUS 250 and 500.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02240835 |
|---|---|
| Brand name | ADVAIR 100 DISKUS |
| Generic / active ingredient | SALMETEROL (SALMETEROL XINAFOATE) : 50 MCG FLUTICASONE PROPIONATE : 100 MCG |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 50 MCG |
| Dosage form | POWDER |
| Route of administration | INHALATION |
| Schedule | Prescription |
| ATC code | R03AK06 SALMETEROL AND FLUTICASONE |
| AHFS class | 12:12.08.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Mar-2002 |
| Original market date | 1999-09-24 00:00:00 |
How is it administered?
Oral inhalation only. Asthma: Twice daily. COPD: ADVAIR DISKUS 250/50 or 500/50 twice daily. Not for acute rescue; use a short-acting beta2-agonist for symptoms. Titrate to lowest effective dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. DISKUS: Store in a dry place. MDI: Protect from frost and direct sunlight; do not puncture or burn canister.
How is it supplied?
ADVAIR DISKUS: Blister strips in a plastic device. ADVAIR MDI: Pressurised metered-dose inhaler.
Contraindications
Hypersensitivity to ingredients; IgE mediated allergic reactions to lactose/milk (Diskus); cardiac tachyarrhythmias; untreated fungal/bacterial/TB respiratory infections; primary treatment of status asthmaticus.
Warnings and precautions
Not for acute symptoms. LABA monotherapy increases asthma-related death risk (class effect). Risk of adrenal suppression, decreased bone density, cataracts, glaucoma, and immunosuppression.
What can be used instead?
Other Canadian products sharing ATC code R03AK06 SALMETEROL AND FLUTICASONE. 11 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADVAIR | 125MCG | AEROSOL, METERED DOSE | GLAXOSMITHKLINE INC | MARKETED | DIN 02245126 |
| ADVAIR | 250 MCG | AEROSOL, METERED DOSE | GLAXOSMITHKLINE INC | MARKETED | DIN 02245127 |
| ADVAIR 250 DISKUS | 250 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | DIN 02240836 |
| ADVAIR 500 DISKUS | 50 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | DIN 02240837 |
| PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI | 50 MCG | POWDER | PHARMASCIENCE INC | MARKETED | DIN 02494507 |
| PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI | 50 MCG | POWDER | PHARMASCIENCE INC | MARKETED | DIN 02494515 |
| PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI | 50 MCG | POWDER | PHARMASCIENCE INC | MARKETED | DIN 02494523 |
| WIXELA INHUB | 250 MCG | POWDER | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02495600 |
| WIXELA INHUB | 50 MCG | POWDER | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02495619 |
| WIXELA INHUB | 50 MCG | POWDER | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02495597 |
Who else supplies SALMETEROL AND FLUTICASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SALMETEROL AND FLUTICASONE appears in 77 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.